2019
Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study
Bilcke J, Antillón M, Pieters Z, Kuylen E, Abboud L, Neuzil KM, Pollard AJ, Paltiel AD, Pitzer VE. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. The Lancet Infectious Diseases 2019, 19: 728-739. PMID: 31130329, PMCID: PMC6595249, DOI: 10.1016/s1473-3099(18)30804-1.Peer-Reviewed Original ResearchConceptsGross domestic productWTP valuesCountry's gross domestic productOptimal strategyCountry-specific willingnessAverage net benefitHealth economic evaluationsGAVI-eligible countriesTyphoid ViPay valueDomestic productVaccine priceWTP thresholdEconomic evaluationVaccine-related costsNet benefitMiddle-income countriesGavi supportVaccine AllianceRoutine immunisationHospital admissionCountriesTCV introductionDALYsTransmission dynamic model
1996
Economic Evaluation of HIV Testing Among Intravenous Drug Users: An Analytic Framework and Its Application to Italy
Villari P, Fattore G, Siegel J, Paltiel A, Weinstein M. Economic Evaluation of HIV Testing Among Intravenous Drug Users: An Analytic Framework and Its Application to Italy. International Journal Of Technology Assessment In Health Care 1996, 12: 336-357. PMID: 8707505, DOI: 10.1017/s0266462300009673.Peer-Reviewed Original ResearchConceptsIntravenous drug usersEarly treatmentDrug usersHIV testing programsLife expectancyEffective early treatmentLow prevalence scenariosHealth care interventionsYears of lifeCost-effectiveness analysisHIV testingAsymptomatic subjectsCare interventionsPrevalence areasHigh prevalenceEconomic evaluationCost-effective procedureHIVPrevalenceTreatmentMore evidenceBehavior changeExpectancyCost savingsCohort